share_log

6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer

6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer

Jemperli Plus化療的申請已接受歐洲藥品管理局的審查,以便將使用範圍擴大到所有原發性晚期或複發性子宮內膜癌患者
美股sec公告 ·  06/24 06:15
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息